Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase

ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data-cut date

100% ORR and CR rate in 5/5 anti-CD19 autologous chimeric antigen receptor T cells (CAR-T) relapsed large B-cell lymphoma (LBCL) patients

86% CR rate in LBCL patients across dose level three (DL3) and above (75% CR rate in LBCL patients across all dose levels)

Both dose level 2 (DL2) and DL3 demonstrated a six-month CR rate of 33%; Patient follow up continues in dose level 4 (DL4) to assess six-month durability

Circulating ADI-001 cells visible through day 28 in peripheral blood at DL4

Company expects to initiate a potentially pivotal study in post-CAR T LBCL patients in the second quarter of 2023; Evaluating potential second pivotal study in earlier-line LBCL patients

Company to host investor webcast Sunday, December 11 at 9:00 am ET

Related Keywords

Texas , United States , American , Francesco Galimi , Adicet Bio , Chen Schor , Adicet Bio Inc , Division Of Cancer Medicine , International Prognostic Index , University Of Texas Md Anderson Cancer Center , Drug Administration , Company Twitter , American Society For Transplantation , Nasdaq , Exchange Commission , Department Of Lymphoma Myeloma , European Medicines Agency , Department Of Lymphoma , Preliminary Efficacy Data , Senior Vice President , Chief Medical Officer , Chief Executive Officer , Sattva Neelapu , Cytokine Release Syndrome , Safety Data , Common Terminology Criteria , Adverse Events , American Society , Cellular Therapy , Biologics License Application , Marketing Authorization Application , Conference Call , Cancer Medicine , Cancer Center , Fast Track Designation , Private Securities Litigation Reform Act , Annual Report ,